• Contact Us

The Full ASGCT 27th Annual Meeting Abstracts Collection is NOW LIVE! Click here to read the full collection.

• Annual Meeting
  • Register
  • Sponsor & Exhibit
  • Future Annual Meetings
  • Annual Meeting Archives

  • Program
    • Workshops
    • Schedule at a Glance

  • Abstracts
    • Submit
    • Present
    • Awards
    • Topics
• Membership
  • My Profile
  • Member Dashboard
  • Awards
  • Scientific Committees

  • Become a Member
  • Career Center
  • Membership Directory
  • Standing Committees

  • Economy-Based Rates
  • New Investigator Center of Educational Resources (NICER)
  • Elections
  • Volunteer
• Events
  • 2024 Advancing Gene and Cell Therapies for Cancer
    • Program
  • Platform Q + ASGCT: Application and Consideration of Treatment Strategies for Relapsed/Refractory MM
  • FDA & ASGCT: Immune Responses to AAV Vectors
  • Community Lunch & Learns

  • ASGCT Annual Meeting
  • Cell Press Webinar: Advances in Viral Vector Gene Delivery for CT Biomanufacturing
  • Policy Summit
  • Professional Development Cafés
  • Non-ASGCT Events

  • Around the World: Innovation in Japan
  • Molecular Therapy Presents: Targets and Biomarkers
  • ASGCT Insights
    • Past Sessions
• Awards
  • Annual Meeting Awards
    • Outstanding Achievement Award
    • Outstanding New Investigator Awards
    • George Stamatoyannopoulos Mentorship Award
    • Award for Excellence in Advancing Diversity, Equity, and Inclusion
    • Exemplary Service Award

  • Career Development Awards
  • Congressional Policy Fellowship

  • Diversity, Equity, & Inclusion Awards
  • Mavis Agbandje-McKenna Scholarship and Fund
• Outreach
  • Clinical Trials Finder
  • Community Quick Takes
    • Informed Consent
    • State of the Field Highlights + Approvals for CGT in 2023
  • Diversity, Equity, and Inclusion
  • Global Outreach
    • Global Gene Therapy Training Course

  • Patient Education: Gene Therapy 101
    • Gene Therapy Basics
    • Gene Therapy Approaches
    • Clinical Trials Process
    • Vectors 101
    • Gene Editing

  • Patient Education: Condition Treatments
    • Beta Thalassemia & Other Blood Disorders
    • CALD and MLD
    • Spinal Muscular Atrophy
    • CAR-T Basics
    • Hemophilia
• Publications
  • ASGCT Blog
  • PlatformQ + ASGCT: Can Gene Therapy Transform the Lives of Patients with GSD1a?
  • The Vector
    • The Vector Archive
  • Landscape Report

  • ASGCT Podcast Network
    • Giants of Gene Therapy
    • The Issue
    • The Molecular Therapy Podcast
  • The Advocate
    • Subscribe to The Advocate

  • Molecular Therapy Family
    • Molecular Therapy Presents Targets and Biomarkers
    • Cell Press Webinar: Advances in Viral Vector Gene Delivery for CT Biomanufacturing
    • Molecular Therapy
    • MT Methods & Clinical Development
    • MT Nucleic Acids
    • MT Oncology
• Advocacy
  • Events and Opportunities
    • Policy Summit
    • ASGCT-FDA Liaison Meeting
    • Cell + Gene Therapy Science Series
    • Congressional Policy Fellowship
    • FDA & ASGCT: Immune Responses to AAV Vectors

  • Policy Priorities
    • Patient Access Overview
    • Regulatory Policy
    • Research Funding

  • The Advocate
    • Subscribe to The Advocate
  • Policy Statements & Letters
• About
  • Leadership
    • Board of Directors
    • Scientific Committees
    • Standing Committees
    • Staff

  • Media
  • Our Culture
  • Strategic Plan
  • Meeting Code of Conduct
  • Terms and Conditions

  • Mission & Vision
    • Bylaws
  • Support ASGCT
    • Annual Meeting Support
    • Advertise in ASGCT Publications
    • Digital Programs
    • Giving
    • Year-Round Support

2024

Q1 2024

The field earned the approval of three new therapies—a CAR-T therapy for myeloma in China, an AAV gene therapy for hemophilia B in Canada, and an autologous cell therapy for melanoma in the United States.

Read the Report